Abstract: Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

Abstract: The invention relates to a cutting insert having an essentially parallelepiped-shaped basic body with two larger spaced-apart longitudinal surfaces (10,11) which are connected to one another by two smaller transverse surfaces (12, 13) and two smaller longitudinal surfaces (14) designed as rake faces, wherein the smaller longitudinal surfaces (14) form with the adjacent surfaces a respective, encircling, closed cutting line which forms the cutting edges and rounded-off cutting corners, and the larger longitudinal surface (10, 11) merges on both sides via respective rounded-off edges into the smaller transverse surface (12, 13), and one of the rounded-off cutting corners is designed so as to project relative to a basic shape which is determined by the cutting lines, on both sides, of the larger longitudinal surfaces (10, 11) with the smaller longitudinal surfaces (14).

Abstract: Compounds of a certain formula I, in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, as well as salts thereof are novel effective HDAC inhibitors.

Abstract: Compounds of a certain formula I, in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, as well as salts thereof are novel effective HDAC inhibitors.

Abstract: Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

Abstract: Compounds of a certain formula I, in which R1, R2, R3, R4 and X have the meanings indicated in the description, are novel effective compounds with Eg5 inhibitory, anti-proliferative and/or apoptosis inducing activity.

Abstract: Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

Abstract: Compounds of a certain formula I, in which R1, R2, R3 and R4 have the meanings indicated in the description, are effective Eg5-inhibiting compounds with anti-proliferative and/or apoptosis inducing activity.

Abstract: The invention relates to novel pyrimidine derivatives of Formula (1) which are efficacious inhibitors of protein kinases, in particular of one or more isoforms of the protein kinase B/Akt.

Abstract: The compounds of formula (I), wherein ring D and ring E together form a fused ring system selected from formula (II), (III), (IV), (V), (VI), (VII), and the salts of these compounds are novel, effective inhibitors of histone deacetylases.

Abstract: The invention relates to compounds of formula I, wherein Ra is —C(O)OR1, in which R1 is 1-7C-alkyl, 3-7C-cycloalkyl, or 1-7C-alkyl substituted by one to four substituents independently selected from R2, Rb is -T-Q, in which T is 1-6C-alkylene or 3-7C-cycloalkylene, and either Q is optionally substituted by Rba and/or Rbb and/or Rbc, and is phenyl or naphthyl, or Q is optionally substituted by Rca and/or Rcb, and is Har, or Q is optionally substituted by Rda and/or Rdb, and is Het, or Q is optionally substituted by Rea and/or Reb, and is 3-7C-cycloalkyl, which are useful for the therapy of hyperproliferative diseases, in particular human cancer.

Abstract: Compounds of the formula I in which the substitutents have the definitions provided in the specification, are novel, effective HDAC inhibitors.

Abstract: Compounds of a certain formula I, in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.

Abstract: Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

Abstract: Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

Abstract: Compounds of a certain formula (I), in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and/or apoptosis inducing activity.

Abstract: Compounds of a certain formula (I) in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.

Abstract: Compounds of a certain formula I, in which R1, R2, R3, R4 and X have the meanings indicated in the description, are novel effective compounds with Eg5 inhibitory, anti-proliferative and/or apoptosis inducing activity.

Abstract: Compounds of a certain formula I in which R1, R2, R3 and R4 have the meanings indicated in the description are novel compounds expected to be useful in the therapy of (hyper)proliferative diseases and/or disorders responsive to induction of apoptosis.

Abstract: Compounds of a certain formula (I), in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.